This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A.D.A.M.'s SmartEngage Wins Top Digital Marketing Award At 4th Annual Digital Marketing Canada Summit

Stocks in this article: EBIX

ATLANTA, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Ebix, Inc. (Nasdaq:EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance industry, announced that the Company's A.D.A.M. SmartEngageā„¢ product recently won Best Unbranded Consumer Website/Microsite at the 4 th Annual Digital Marketing Canada Summit October 28-29, 2013 at the West Prince Toronto. Presented by eyeforpharma, Digital Marketing Canada brings together an influential audience of healthcare industry leaders for educational sessions and networking.

SmartEngage is a comprehensive consumer healthcare education tool that includes a multimedia encyclopedia, in-depth reports, complementary and alternative medicine, wellness tools, health navigator and the A.D.A.M. community.

Vice President of A.D.A.M. Soula Chronopoulos said, "The SmartEngage program was designed to provide comprehensive patient education that not only connects the end user to the healthcare organization, but also empowers the patient to take control of their health. Mobile enabled and enhanced with award-winning images and animations, the program engages and informs the user on critical self-care topics, and promotes compliance and patient outreach."

The product is flexible in allowing healthcare organizations to embed the content within their consumer and patient portals, with the ability to customize the content to meet their specific goals.

Soula Chronopoulos added, "Enabling this feature gives the healthcare organization complete ownership of the articles, yet the organization will continue to receive regular medical updates from A.D.A.M. Furthermore, we are evolving the program to support patient journeys that tap into gamification that will provide patients with key information that will help them make informed decisions about their health."

The content is available in English, Portuguese, and Spanish.

In summary this "Next Generation" tool from A.D.A.M. makes complex healthcare subject matter understandable and most importantly usable by the patient so that they really can participate in managing their own health!

About eyeforpharma:

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay up to date with shifting trends and practices within the pharmaceutical industry. We provide industry-focused commentary, events, reports, and other valuable expert-driven content. Our ultimate aim is to facilitate positive change through discussion and debate, enabling dialogue within the industry and driving the positive benefits that pharmaceuticals can offer. We actively respond to the aims and interests of our audience, so please get in touch if you think we can do even more. eyeforpharma is part of FC Business Intelligence Ltd. FC Business Intelligence Ltd is a registered company in England and Wales - Registered number 04388971, 7-9 Fashion Street, London, E1 6PX, UK.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs